SNP snap.

Nobody knows what to recommend anymore when it comes to prostate cancer screening in the general public, though most agree men should be at a sufficient baseline risk of having cancer before opening the Pandora’s biopsy box of annual PSA screening. This secondary analysis of the prospective REDUCE trial, which randomized men to +/- the 5-ɑ-reductase inhibitor dutasteride for prostate cancer prevention, used baseline patient DNA to assess whether a certain array of single nucleotide polymorphisms (SNPs) could predict risk of later developing prostate cancer. It could. TBL: Combining an easily obtained genetic risk score with family history better predicts risk of developing prostate cancer than family history alone, meaning some men may prefer a one-time genetic blood draw to indefinite yearly PSA. | Na, JAMA Netw Open 2019